JP2025090691A5 - - Google Patents

Info

Publication number
JP2025090691A5
JP2025090691A5 JP2025037025A JP2025037025A JP2025090691A5 JP 2025090691 A5 JP2025090691 A5 JP 2025090691A5 JP 2025037025 A JP2025037025 A JP 2025037025A JP 2025037025 A JP2025037025 A JP 2025037025A JP 2025090691 A5 JP2025090691 A5 JP 2025090691A5
Authority
JP
Japan
Prior art keywords
seq
antibody
pharmaceutical formulation
antibody comprises
hcvr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025037025A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025090691A (ja
Filing date
Publication date
Priority claimed from JP2022543445A external-priority patent/JP7674369B2/ja
Application filed filed Critical
Publication of JP2025090691A publication Critical patent/JP2025090691A/ja
Publication of JP2025090691A5 publication Critical patent/JP2025090691A5/ja
Pending legal-status Critical Current

Links

JP2025037025A 2020-01-24 2025-03-10 安定な抗体製剤 Pending JP2025090691A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202062965786P 2020-01-24 2020-01-24
US62/965,786 2020-01-24
JP2022543445A JP7674369B2 (ja) 2020-01-24 2021-01-22 安定な抗体製剤
PCT/US2021/014524 WO2021150829A1 (en) 2020-01-24 2021-01-22 Stable antibody formulation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022543445A Division JP7674369B2 (ja) 2020-01-24 2021-01-22 安定な抗体製剤

Publications (2)

Publication Number Publication Date
JP2025090691A JP2025090691A (ja) 2025-06-17
JP2025090691A5 true JP2025090691A5 (cg-RX-API-DMAC7.html) 2025-07-15

Family

ID=74858743

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022543445A Active JP7674369B2 (ja) 2020-01-24 2021-01-22 安定な抗体製剤
JP2025037025A Pending JP2025090691A (ja) 2020-01-24 2025-03-10 安定な抗体製剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022543445A Active JP7674369B2 (ja) 2020-01-24 2021-01-22 安定な抗体製剤

Country Status (13)

Country Link
US (2) US12337199B2 (cg-RX-API-DMAC7.html)
EP (1) EP4093435A1 (cg-RX-API-DMAC7.html)
JP (2) JP7674369B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220131923A (cg-RX-API-DMAC7.html)
CN (1) CN115243718A (cg-RX-API-DMAC7.html)
AU (1) AU2021210942A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022014240A2 (cg-RX-API-DMAC7.html)
CA (1) CA3162569A1 (cg-RX-API-DMAC7.html)
CL (2) CL2022001989A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022010254A2 (cg-RX-API-DMAC7.html)
IL (1) IL294375B2 (cg-RX-API-DMAC7.html)
MX (1) MX2022008949A (cg-RX-API-DMAC7.html)
WO (1) WO2021150829A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112545886A (zh) 2015-03-10 2021-03-26 里珍纳龙药品有限公司 无菌刺穿系统和方法
US20200148750A1 (en) 2016-07-21 2020-05-14 Emory University Ebola Virus Antibodies and Binding Agents Derived Therefrom
CA3055583A1 (en) 2017-05-05 2018-11-08 Regeneron Pharmaceuticals, Inc. Auto-injector
MX2022008949A (es) * 2020-01-24 2022-08-15 Regeneron Pharma Formulacion de anticuerpos estable.
USD1007676S1 (en) 2021-11-16 2023-12-12 Regeneron Pharmaceuticals, Inc. Wearable autoinjector
WO2024259313A1 (en) 2023-06-16 2024-12-19 Regeneron Pharamceuticals, Inc. Medical device packaging and related methods
TW202529831A (zh) 2023-10-02 2025-08-01 美商再生元醫藥公司 藥物遞輸裝置安全系統
WO2025171492A1 (en) 2024-02-14 2025-08-21 Alpha-9 Oncology Inc. Stable radiopharmaceutical compositions and uses thereof
US20260221053A1 (en) 2025-01-29 2026-07-30 Regeneron Pharmaceuticals, Inc. Drug delivery devices, safety systems, training devices, and methods of use thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
AU7089600A (en) 1999-08-30 2001-03-26 U.S. Army Medical Research Institute Of Infectious Diseases Monoclonal antibodies and vaccines against epitopes on the ebola virus glycoprotein
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
US6875433B2 (en) 2002-08-23 2005-04-05 The United States Of America As Represented By The Secretary Of The Army Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein
EP2262832A4 (en) 2008-02-01 2011-03-09 Ca Minister Health & Welfare MONOCLONAL ANTIBODIES TO EBOLA AND MARBURG VIRUSES
AR070315A1 (es) * 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
WO2010048615A2 (en) 2008-10-24 2010-04-29 The Government Of The United States Of America As Represented By The Secretary, Department Of Health & Human Services, Center For Disease Control And Prevention Human ebola virus species and compositions and methods thereof
WO2012135408A1 (en) 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
WO2014031718A1 (en) 2012-08-23 2014-02-27 Merck Sharp & Dohme Corp. Stable formulations of antibodies to tslp
JP6041580B2 (ja) * 2012-08-28 2016-12-14 京セラ株式会社 電子機器、制御方法、及び制御プログラム
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
HRP20201334T1 (hr) 2015-04-17 2020-11-27 Bristol-Myers Squibb Company Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba
SG11201909941QA (en) * 2017-05-02 2019-11-28 Merck Sharp & Dohme Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
US20210054079A1 (en) * 2018-04-25 2021-02-25 Medimmune Limited Formulations of human anti-pd-li antibodies
MX2022008949A (es) * 2020-01-24 2022-08-15 Regeneron Pharma Formulacion de anticuerpos estable.

Similar Documents

Publication Publication Date Title
CA2870338C (en) Lyophilised and aqueous anti-cd40 antibody formulations
JP5918246B2 (ja) 抗インターロイキン−4受容体(il−4r)抗体を含有する安定化製剤
FI3606504T3 (fi) Stabiili vasta-aineformulaatio
JP2022532927A5 (cg-RX-API-DMAC7.html)
JP2020518600A5 (cg-RX-API-DMAC7.html)
RU2006120950A (ru) Антитело к cd40: препарат и способы
JP2014074034A (ja) Tnf−アルファ関連疾患の治療用ヒト抗体の製剤
IE57397B1 (en) Pharmaceutical compositions
ES2267591T3 (es) Combinaciones farmaceuticas que comprenden un antagonista del receptor p2t y melagatran.
JP2024531151A5 (cg-RX-API-DMAC7.html)
JP2024515968A5 (cg-RX-API-DMAC7.html)
CN113797333A (zh) 一种新型冠状病毒抗体的药物组合物及其用途
EP3867271A1 (en) Formulations of anti-rsv antibodies and methods of use thereof
JP2024544523A5 (cg-RX-API-DMAC7.html)
JP2023540025A5 (cg-RX-API-DMAC7.html)
JP2003521518A (ja) モノチオグリセロール、l−システインまたはチオグリコール酸とともにペメトレクストを含む医薬組成物
WO2023186173A1 (zh) 包含针对狂犬病病毒g蛋白的双特异性抗体的药物制剂及其制备方法
JP2009521473A5 (cg-RX-API-DMAC7.html)
US20250090622A1 (en) Angiotensin compositions and methods related thereto
JP2023502398A5 (cg-RX-API-DMAC7.html)
JP2022519796A5 (cg-RX-API-DMAC7.html)
AR083338A1 (es) Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r)
JP2026016480A5 (cg-RX-API-DMAC7.html)
PT92163B (pt) Processo para a preparacao de uma composicao mdm liofilizada
JPS5933297A (ja) ウイルス感染症の予防及び治療剤